Aspirin in the prevention of cardiovascular events in patients with diabetes

References

• American Diabetes Association. Statistics About Diabetes Data from the National Diabetes Statistics Report, 2014 (released June 10, 2014) Overall Numbers, Diabetes and Prediabetes. 2014. [ cited 2014 Nov 26] Available from: http://www.diabetes.org/diabetes-basics/statistics/.
   Google Scholar
• Geiss LS, Wang J, Cheng YJ, et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980–2012. JAMA. 2014;312:1218–1226.
   PubMed Web of Science ®Google Scholar
• Sarwar N, Gao P, Seshasai SR, et al The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–2222.
   PubMed Web of Science ®Google Scholar
• Cubbon RM, Abbas A, Wheatcroft SB, et al. Diabetes mellitus and mortality after acute coronary syndrome as a first or recurrent cardiovascular event. PLoS One. 2008;3:e3483.
   PubMed Web of Science ®Google Scholar
• Leander K, Wiman B, Hallqvist J, et al. Primary risk factors influence risk of recurrent myocardial infarction/death from coronary heart disease: results from the Stockholm Heart Epidemiology Program (SHEEP). Eur J Cardiovasc Prev Rehabil. 2007;14:532–537.
   PubMedGoogle Scholar
• Bonow RO, Bohannon N, Hazzard W. Risk stratification in coronary artery disease and special populations. Am J Med. 1996;101:4A17S–22S.
   PubMedGoogle Scholar
• American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37:S14–S80.
   PubMed Web of Science ®Google Scholar
• Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035–3087.
   PubMed Web of Science ®Google Scholar
• Nicolucci A, De BG, Sacco M, et al. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J. 2007;28:1925–1927.
   PubMed Web of Science ®Google Scholar
• Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis. 2009;52:141–152.
   PubMed Web of Science ®Google Scholar
• Grove EL. Antiplatelet effect of aspirin in patients with coronary artery disease. Dan Med J. 2012;59:B4506.
   PubMed Web of Science ®Google Scholar
• Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–2494.
   PubMed Web of Science ®Google Scholar
• Di Minno MN, Guida A, Camera M, et al. Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention. Ann Med. 2011;43:531–544.
   PubMed Web of Science ®Google Scholar
• Freynhofer MK, Bruno V, Wojta J, et al. The role of platelets in athero-thrombotic events. Curr Pharm Des. 2012;18:5197–5214.
   PubMed Web of Science ®Google Scholar
• Vazzana N, Ranalli P, Cuccurullo C, et al. Diabetes mellitus and thrombosis. Thromb Res. 2012;129:371–377.
   PubMed Web of Science ®Google Scholar
• Wallace EL, Smyth SS. Targeting platelet thrombin receptor signaling to prevent thrombosis. Pharmaceuticals (Basel). 2013;6:915–928.
   PubMedGoogle Scholar
• Hess K. The vulnerable blood. Coagulation and clot structure in diabetes mellitus. Hamostaseologie. 2015;35:25–33.
   PubMed Web of Science ®Google Scholar
• FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676–688.
   PubMed Web of Science ®Google Scholar
• Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980;17:317–327.
   PubMed Web of Science ®Google Scholar
• Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311:1206–1211.
   PubMed Web of Science ®Google Scholar
• Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366–1372.
   PubMed Web of Science ®Google Scholar
• Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975;72:3073–3076.
   PubMed Web of Science ®Google Scholar
• Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287–1294.
   PubMed Web of Science ®Google Scholar
• Sostres C, Lanas A. Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol. 2011;8:385–394.
   PubMed Web of Science ®Google Scholar
• Rainsford KD. Aspirin and related drugs. New York, NY: Taylor & Francis; 2004.
   Google Scholar
• Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005;46:1705–1709.
   PubMed Web of Science ®Google Scholar
• Patrignani P, Tacconelli S, Piazuelo E, et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. J Thromb Haemost. 2014;12:1320–1330.
   PubMed Web of Science ®Google Scholar
• Patrono C, García Rodríguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–2383.
   PubMed Web of Science ®Google Scholar
• Würtz M, Hvas AM, Jensen LO, et al. 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. Int J Cardiol. 2014;175:274–279.
   PubMed Web of Science ®Google Scholar
• Perneby C, Wallen NH, Rooney C, et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost. 2006;95:652–658.
   PubMed Web of Science ®Google Scholar
• Rocca B, Santilli F, Pitocco D, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012;10:1220–1230.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Collins R, et al; Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860.
   PubMed Web of Science ®Google Scholar
• Butalia S, Leung AA, Ghali WA, et al. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol. 2011;10:25.
   PubMed Web of Science ®Google Scholar
• Bulugahapitiya U, Siyambalapitiya S, Sithole J, et al. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26:142–148.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–2141.
   PubMed Web of Science ®Google Scholar
• Okada S, Morimoto T, Ogawa H, et al. Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. Diabetes Care. 2011;34:1277–1283.
   PubMed Web of Science ®Google Scholar
• Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
   PubMed Web of Science ®Google Scholar
• Saito Y, Morimoto T, Ogawa H, et al. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care. 2011;34:280–285.
   PubMed Web of Science ®Google Scholar
• Soejima H, Ogawa H, Morimoto T, et al. Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: subanalysis from the JPAD trial. J Cardiol. 2013;62:165–170.
   PubMed Web of Science ®Google Scholar
• Soejima H, Ogawa H, Morimoto T, et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circ J. 2012;76:1526–1532.
   PubMed Web of Science ®Google Scholar
• Okada S, Morimoto T, Ogawa H, et al. Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circ J. 2013;77:3023–3028.
   PubMed Web of Science ®Google Scholar
• Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract. 2010;87:211–218.
   PubMed Web of Science ®Google Scholar
• De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531.
   PubMed Web of Science ®Google Scholar
• Stavrakis S, Stoner JA, Azar M, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Am J Med Sci. 2011;341:1–9.
   PubMed Web of Science ®Google Scholar
• Simpson SH, Gamble JM, Mereu L, et al. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med. 2011;26:1336–1344.
   PubMed Web of Science ®Google Scholar
• Xie M, Shan Z, Zhang Y, et al. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. PLoS One. 2014;9:e90286.
   PubMed Web of Science ®Google Scholar
• Younis N, Williams S, Ammori B, et al. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opin Pharmacother. 2010;11:1459–1466.
   PubMed Web of Science ®Google Scholar
• Calvin AD, Aggarwal NR, Murad MH, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care. 2009;32:2300–2306.
   PubMed Web of Science ®Google Scholar
• Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care. 2010;33:1395–1402.
   PubMed Web of Science ®Google Scholar
• Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:209–216.
   PubMed Web of Science ®Google Scholar
• McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119:624–638.
   PubMed Web of Science ®Google Scholar
• Machlus KR, Italiano JE Jr. The incredible journey: from megakaryocyte development to platelet formation. J Cell Biol. 2013;201:785–796.
   PubMed Web of Science ®Google Scholar
• Tasdemir E, Toptas T, Demir C, et al. Aspirin resistance in patients with type II diabetes mellitus. Ups J Med Sci. 2014;119:25–31.
   PubMed Web of Science ®Google Scholar
• Fateh-Moghadam S, Plockinger U, Cabeza N, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol. 2005;42:99–103.
   PubMed Web of Science ®Google Scholar
• Simpson SH, Abdelmoneim AS, Omran D, et al. Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin. Am J Med. 2014;127:95, e1–95, e9.
   Web of Science ®Google Scholar
• Cohen HW, Crandall JP, Hailpern SM, et al. Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complications. 2008;22:224–228.
   PubMed Web of Science ®Google Scholar
• Ertugrul DT, Tutal E, Yildiz M, et al. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95:2897–2901.
   PubMed Web of Science ®Google Scholar
• Watala C, Boncler M, Gresner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep. 2005;57(Suppl):42–58.
   PubMed Web of Science ®Google Scholar
• Salama MM, Morad AR, Saleh MA, et al. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors. J Clin Pharm Ther. 2012;37:630–636.
   PubMed Web of Science ®Google Scholar
• DiChiara J, Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007;56:3014–3019.
   PubMed Web of Science ®Google Scholar
• Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res. 2004;113:101–113.
   PubMed Web of Science ®Google Scholar
• Watala C, Pluta J, Golanski J, et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med (Berl). 2005;83:148–158.
   PubMed Web of Science ®Google Scholar
• Singla A, Antonino MJ, Bliden KP, et al. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J. 2009;158:784–786.
   PubMed Web of Science ®Google Scholar
• Mylotte D, Kavanagh GF, Peace AJ, et al. Platelet reactivity in type 2 diabetes mellitus: a comparative analysis with survivors of myocardial infarction and the role of glycaemic control. Platelets. 2012;23:439–446.
   PubMed Web of Science ®Google Scholar
• Christensen KH, Grove EL, Wurtz M, et al. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. Platelets. 2015;26:230–235.
   PubMed Web of Science ®Google Scholar
• Luscher TF, Creager MA, Beckman JA, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation. 2003;108:1655–1661.
   PubMed Web of Science ®Google Scholar
• Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, et al. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5:444–470.
   PubMedGoogle Scholar
• Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets. 2006;17:577–585.
   PubMed Web of Science ®Google Scholar
• Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol. 2003;92:1362–1365.
   PubMed Web of Science ®Google Scholar
• Lubitz SA, Benjamin EJ, Ellinor PT. Atrial fibrillation in congestive heart failure. Heart Fail Clin. 2010;6:187–200.
   PubMedGoogle Scholar
• Davì G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med. 1990;322:1769–1774.
   PubMed Web of Science ®Google Scholar
• Davì G, Rini GB, Averna M, et al. Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics. Thromb Res. 1982;26:359–370.
   PubMed Web of Science ®Google Scholar
• Kim JH, Bae HY, Kim SY. Clinical marker of platelet hyperreactivity in diabetes mellitus. Diabetes Metab J. 2013;37:423–428.
   PubMedGoogle Scholar
• Zaccardi F, Rocca B, Pitocco D, et al. Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis. Diabetes Metab Res Rev. 2015;31:402–410.
   PubMed Web of Science ®Google Scholar
• Lee EY, Kim SJ, Song YJ, et al. Immature platelet fraction in diabetes mellitus and metabolic syndrome. Thromb Res. 2013;132:692–695.
   PubMed Web of Science ®Google Scholar
• Shah B, Sha D, Xie D, et al. The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume: the National Health And Nutrition Examination Survey, 1999–2004. Diabetes Care. 2012;35:1074–1078.
   PubMed Web of Science ®Google Scholar
• DiMinno G, Silver MJ, Cerbone AM, et al. Increased binding of fibrinogen to platelets in diabetes: the role of prostaglandins and thromboxane. Blood. 1985;65:156–162.
   PubMed Web of Science ®Google Scholar
• Winocour PD, Bryszewska M, Watala C, et al. Reduced membrane fluidity in platelets from diabetic patients. Diabetes. 1990;39:241–244.
   PubMed Web of Science ®Google Scholar
• Watala C, Boncer M, Golanski J, et al. Platelet membrane lipid fluidity and intraplatelet calcium mobilization in type 2 diabetes mellitus. Eur J Haematol. 1998;61:319–326.
   PubMed Web of Science ®Google Scholar
• Tschoepe D, Roesen P, Kaufmann L, et al. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest. 1990;20:166–170.
   PubMed Web of Science ®Google Scholar
• Cabeza N, Li Z, Schulz C, et al. Surface expression of collagen receptor Fc receptor-gamma/glycoprotein VI is enhanced on platelets in type 2 diabetes and mediates release of CD40 ligand and activation of endothelial cells. Diabetes. 2004;53:2117–2121.
   PubMed Web of Science ®Google Scholar
• Hu H, Li N, Yngen M, et al. Enhanced leukocyte-platelet cross-talk in Type 1 diabetes mellitus: relationship to microangiopathy. J Thromb Haemost. 2004;2:58–64.
   PubMed Web of Science ®Google Scholar
• Razmara M, Hjemdahl P, Ostenson CG, et al. Platelet hyperprocoagulant activity in Type 2 diabetes mellitus: attenuation by glycoprotein IIb/IIIa inhibition. J Thromb Haemost. 2008;6:2186–2192.
   PubMed Web of Science ®Google Scholar
• Mijovic R, Kovacevic N, Zarkov M, et al. Reticulated platelets and antiplatelet therapy response in diabetic patients. J Thromb Thrombolysis. 2015;40:203–210.
   PubMed Web of Science ®Google Scholar
• Ingram M, Coopersmith A. Reticulated platelets following acute blood loss. Br J Haematol. 1969;17:225–229.
   PubMed Web of Science ®Google Scholar
• Karpatkin S. Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest. 1969;48:1083–1087.
   PubMed Web of Science ®Google Scholar
• DiMinno G, Silver MJ, Cerbone AM, et al. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood. 1986;68:886–891.
   PubMed Web of Science ®Google Scholar
• Addad F, Chakroun T, Elalamy I, et al. Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. Int J Hematol. 2010;92:296–301.
   PubMed Web of Science ®Google Scholar
• Lemkes BA, Bahler L, Kamphuisen PW, et al. The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. J Thromb Haemost. 2012;10:639–646.
   PubMed Web of Science ®Google Scholar
• Spectre G, Arnetz L, Östenson CG, et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost. 2011;106:491–499.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv. 2011;4:180–187.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95:1218–1222.
   PubMed Web of Science ®Google Scholar
• Dillinger JG, Drissa A, Sideris G, et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J. 2012;164:600–606.
   PubMed Web of Science ®Google Scholar
• Bethel MA, Harrison P, Sourij H, et al. Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. Diabet Med. 2015 Jun 4. DOI:10.1111/dme.12828. [Epub ahead of print].
   Google Scholar
• Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125:882–887.
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–1310.
   PubMed Web of Science ®Google Scholar
• Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20:1512–1517.
   PubMed Web of Science ®Google Scholar
• Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–1224.
   PubMed Web of Science ®Google Scholar
• Hall HM, Banerjee S, McGuire DK. Variability of clopidogrel response in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2011;8:245–253.
   PubMed Web of Science ®Google Scholar
• Bhavaraju K, Georgakis A, Jin J, et al. Antagonism of P2Y(1)(2) reduces physiological thromboxane levels. Platelets. 2010;21:604–609.
   PubMed Web of Science ®Google Scholar
• Armstrong PC, Dhanji AR, Tucker AT, et al. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost. 2010;8:613–615.
   PubMed Web of Science ®Google Scholar
• Shankar H, Garcia A, Prabhakar J, et al. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost. 2006;4:638–647.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Malinin AI, Pokov A, et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix use for treatment of diabetes (PLUTO-Diabetes) trial. Am Heart J. 2008;155:93–97.
   PubMedGoogle Scholar
• Duzenli MA, Ozdemir K, Aygul N, et al. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin. Am J Cardiol. 2008;102:396–400.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Steinhubl SR, Bhatt DL, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol. 2009;103:1359–1363.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717.
   PubMed Web of Science ®Google Scholar
• Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279–284.
   PubMed Web of Science ®Google Scholar
• Mateo JF, Gil-Guillen VF, Mateo E, et al. Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. Int J Clin Pract. 2006;60:422–428.
   PubMed Web of Science ®Google Scholar
• Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157–1168.
   PubMed Web of Science ®Google Scholar
• Patrick J, Dillaha L, Armas D, et al. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. Postgrad Med. 2015;127:573–580.
   PubMed Web of Science ®Google Scholar
• Frieden TR. Use of selected clinical preventive services among adults–United States, 2007–2010. MMWR Morb Mortal Wkly Rep. 2012;61(Suppl):1–2.
   PubMedGoogle Scholar